Literature DB >> 2395402

Experimental model of immune-mediated hearing loss using cross-species immunization.

C R Orozco1, J K Niparko, B C Richardson, D F Dolan, M U Ptok, R A Altschuler.   

Abstract

The presence of immune-mediated hearing loss was investigated in an animal model. Eight guinea pigs and four mice underwent immunizations with a preparation of chick or guinea pig cochlear tissue and Freund's adjuvant. Hearing thresholds were monitored by auditory brainstem response (ABR) testing over a 5-week period after immunization. The serum and temporal bones of test and control animals were then examined using an enzyme-linked immunosorbent assay (ELISA), immunocytochemical, and histological techniques. Hearing loss of 20 dB or greater occurred in eight animals. ELISA demonstrated antibodies to cochlear antigens in the sera of all test animals. Immunocytochemistry revealed immunostaining of hair cell stereocilia in the organ of Corti and saccule. Endolymphatic hydrops, and organ of Corti degeneration was observed in the temporal bones of three animals. This study provides evidence to suggest that cross-species immunization with cochlear antigens might produce a humoral response that can be associated with inner ear pathologic change and sensorineural hearing loss.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2395402     DOI: 10.1288/00005537-199009000-00006

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  2 in total

1.  Detection of inner ear disease autoantibodies by immunoblotting.

Authors:  M Y Cao; M Gersdorff; N Deggouj; M Warny; J P Tomasi
Journal:  Mol Cell Biochem       Date:  1995-05-24       Impact factor: 3.396

2.  Case Report: Anti-NMDA Receptor Encephalitis With Bilateral Hearing Loss as the Initial Symptom.

Authors:  Hongjiang Cheng; Fengbing Yang; Jing Zhang; Lina Xu; Longbin Jia; Doudou Zhao; Wei Liu; Huimin Li
Journal:  Front Neurol       Date:  2021-03-17       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.